BDA Partners is pleased to announce Bristol Myers Squibb (\u201cBMS\u201d), advised by William Blair in conjunction with BDA Partners, has agreed to divest its manufacturing facility in Couvet, Switzerland to WuXi STA, the CDMO subsidiary of WuXi AppTec. The value of the transaction is not disclosed.<\/p>\n\n\n\n
BMS is a leading global pharma company. The Couvet site is a newly constructed, state-of-the-art manufacturing and packaging facility, with commercial-scale production capacity for capsule and tablet dosage forms. The facility was designed with industry leading energy efficiency and environmental standards and was constructed to accommodate future growth.<\/p>\n\n\n\n
The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization (CDMO). WuXi STA will acquire the Couvet site\u2019s operations and assets, which include the plant and equipment, as well as a workforce with technical capabilities and expertise. The acquisition will enhance WuXi STA\u2019s existing capabilities while growing capacity to support its partners\u2019 life-saving work.<\/p>\n\n\n\n